Market Snapshot

S&P Futures
4,197.00
Dow Futures
34,459.00
NASDAQ Futures
13,613.25

6.93$-0.45 -6.10%
At close    04:00 PM   
From: To:

Stock Snapshot

7.38
Prev. Close
6.79
Open
697.23M
Market Cap
25.80M
Number of Shares
6.33
Day Low
7.22
Day High
6.93
-
P/E Ratio
114.75M
Free Float in %
-0.34
EPS 2021
1.12
Book Value per Share
1.26
Cash Flow per Share
Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT) stock rallied over -6.10% intraday to trade at $6.93 per share on NASDAQ. The stock opened with a fall of -7.99% at $6.79 and touched an intraday high of $7.22, 2.17% against the last close of $7.38. The stock went to a low of $6.33 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-05-06$6.79$6.93$6.93$7.22$6.3322,598,287
2021-05-05$8.28$7.38$7.38$8.44$7.3233,040,100
2021-05-04$9.50$8.76$8.76$9.55$8.1871,557,400
2021-05-03$9.97$8.02$8.02$10.56$7.91108,169,600
2021-04-30$9.52$10.78$10.78$11.11$9.35112,224,800
2021-04-29$9.69$9.21$9.21$11.00$8.92123,332,500
2021-04-28$8.07$8.44$8.44$8.87$7.7850,801,900
2021-04-27$6.21$8.33$8.33$9.50$6.14220,596,000
2021-04-26$5.68$6.06$6.06$6.08$5.544,961,600
2021-04-23$5.83$5.56$5.56$5.83$5.425,543,200
2021-04-22$5.93$5.76$5.76$6.14$5.697,354,500
Vaxart, Inc.
170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States

http://vaxart.com
650 550 3500
Employees
28
Sector
Healthcare
Sales or Revenue
4.00M
Industry
Biotechnology
5Y Sales Change
-15.30
Fiscal Year Ends
2020-12-30
Dr. Sean N. Tucker
Founder & Chief Scientific Officer
Ms. Margaret A. Echerd
VP, Corp. Controller & Principal Accounting Officer
Mr. Cezar Andrei Floroiu M.B.A.
CEO, Pres, Principal Financial Officer & Director
Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.